This month’s alternative data insights include the weight-loss drug boom, the APAC funding scene, and the challenges facing data centre buildouts.

Changes in healthcare datasets as semaglutide patent cliff looms

Last month, PitchBook reported on Eli Lilly’s acquisition of Kelonia, stating that this shows healthcare providers are diversifying beyond GLP-1s following the weight-loss drug boom. Though Eli Lilly gained $36.5bn from GLP-1s in 2025, PitchBook noted that profits may decline as more options enter the market. It suggested that Eli Lilly’s expansion into CAR-T technology (through Kelonia) shows how healthcare providers are diversifying to stay relevant. PitchBook said it is seeing a recent boost in biotech, as opposed to the weight-loss category.